Enovis (NYSE:ENOV) Price Target Raised to $38.00

Enovis (NYSE:ENOV) had its price objective boosted by stock analysts at Needham & Company LLC from $34.00 to $38.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC‘s target price would indicate a potential upside of 33.36% from the company’s previous close.

Several other research analysts also recently commented on ENOV. UBS Group reaffirmed a “buy” rating and issued a $44.00 target price on shares of Enovis in a research note on Monday, October 5th. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. BTIG Research increased their price target on shares of Enovis from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday. BMO Capital Markets set a $27.00 price target on shares of Enovis in a report on Tuesday, September 1st. Finally, Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Enovis has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Enovis Trading Up 16.7%

ENOV stock traded up $4.08 during trading on Thursday, hitting $28.50. 5,319,363 shares of the company traded hands, compared to its average volume of 1,269,304. The firm has a market capitalization of $1.64 billion, a PE ratio of -1.48 and a beta of 1.31. Enovis has a 1 year low of $16.70 and a 1 year high of $32.41. The company has a 50-day moving average of $19.79 and a 200-day moving average of $23.05. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.88 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.11. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The firm had revenue of $558.73 million during the quarter, compared to the consensus estimate of $557.12 million. During the same quarter in the previous year, the company posted $0.75 earnings per share. The business’s revenue was up 1.8% on a year-over-year basis. Analysts predict that Enovis will post 3.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Damien Mcdonald acquired 13,035 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was bought at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the acquisition, the chief executive officer directly owned 247,077 shares in the company, valued at approximately $4,731,524.55. The trade was a 5.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Oliver Engert acquired 2,660 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was acquired at an average cost of $18.80 per share, for a total transaction of $50,008.00. Following the completion of the transaction, the insider directly owned 63,898 shares in the company, valued at $1,201,282.40. This represents a 4.34% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 23,293 shares of company stock worth $449,599. Corporate insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

Several institutional investors have recently added to or reduced their stakes in ENOV. Illinois Municipal Retirement Fund boosted its holdings in shares of Enovis by 22.4% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 38,366 shares of the company’s stock valued at $701,000 after acquiring an additional 7,028 shares during the last quarter. Private Management Group Inc. grew its stake in shares of Enovis by 31.3% in the third quarter. Private Management Group Inc. now owns 1,792,429 shares of the company’s stock worth $32,748,000 after acquiring an additional 427,347 shares during the period. Fulcrum Asset Management LLP grew its stake in shares of Enovis by 2,739.4% in the third quarter. Fulcrum Asset Management LLP now owns 20,330 shares of the company’s stock worth $375,000 after acquiring an additional 19,614 shares during the period. Villanova Investment Management Co raised its holdings in shares of Enovis by 10.2% during the third quarter. Villanova Investment Management Co now owns 148,424 shares of the company’s stock valued at $2,712,000 after purchasing an additional 13,740 shares during the last quarter. Finally, Bfsg LLC lifted its position in Enovis by 24.6% during the third quarter. Bfsg LLC now owns 13,282 shares of the company’s stock valued at $243,000 after purchasing an additional 2,622 shares during the period. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Enovis News Summary

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported Q3 earnings of $0.88 per share, topping analyst estimates of about $0.76–$0.77 and improving from $0.75 a year earlier. Revenue of $558.7 million was slightly above consensus, though year-over-year growth was modest at 1.8%. Enovis Q3 2026 results
• Positive Sentiment: The company announced a $200 million share buyback, which could support per-share results and signal management confidence in the business. Enovis announces $200 million equity buyback
• Positive Sentiment: BTIG Research raised its price target to $42 from $36 and maintained a Buy rating, adding to the bullish outlook after the earnings release. BTIG Research ratings
• Neutral Sentiment: Revenue was close to expectations, so the earnings beat was driven more clearly by per-share earnings than by stronger-than-expected sales growth.
• Negative Sentiment: Fundamentals provided with the report show a sharply negative net margin, a profitability concern despite the quarterly EPS beat.

About Enovis

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.